OGN vs. GSK
Compare and contrast key facts about Organon & Co. (OGN) and GlaxoSmithKline plc (GSK).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: OGN or GSK.
Key characteristics
OGN | GSK | |
---|---|---|
YTD Return | 53.62% | 23.30% |
1Y Return | 11.71% | 30.28% |
3Y Return (Ann) | -10.03% | 8.54% |
Sharpe Ratio | 0.30 | 1.61 |
Daily Std Dev | 42.00% | 18.09% |
Max Drawdown | -69.56% | -55.72% |
Current Drawdown | -38.43% | -0.98% |
Fundamentals
OGN | GSK | |
---|---|---|
Market Cap | $5.25B | $92.19B |
EPS | $4.08 | $2.72 |
PE Ratio | 5.00 | 16.57 |
PEG Ratio | 0.00 | 1.09 |
Revenue (TTM) | $6.35B | $30.74B |
Gross Profit (TTM) | $3.89B | $19.92B |
EBITDA (TTM) | $1.59B | $10.54B |
Correlation
The correlation between OGN and GSK is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
OGN vs. GSK - Performance Comparison
In the year-to-date period, OGN achieves a 53.62% return, which is significantly higher than GSK's 23.30% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
OGN vs. GSK - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Organon & Co. (OGN) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
OGN vs. GSK - Dividend Comparison
OGN's dividend yield for the trailing twelve months is around 5.20%, more than GSK's 4.08% yield.
TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Organon & Co. | 5.20% | 7.77% | 4.01% | 1.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
GlaxoSmithKline plc | 4.08% | 3.75% | 4.72% | 4.93% | 5.53% | 4.35% | 5.53% | 5.80% | 6.89% | 5.94% | 6.18% | 4.49% |
Drawdowns
OGN vs. GSK - Drawdown Comparison
The maximum OGN drawdown since its inception was -69.56%, which is greater than GSK's maximum drawdown of -55.72%. Use the drawdown chart below to compare losses from any high point for OGN and GSK. For additional features, visit the drawdowns tool.
Volatility
OGN vs. GSK - Volatility Comparison
Organon & Co. (OGN) has a higher volatility of 7.79% compared to GlaxoSmithKline plc (GSK) at 4.69%. This indicates that OGN's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
OGN vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Organon & Co. and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities